Evaluate whether integration of HeartCare (AlloMap + AlloSure) into routine post-transplant surveillance reduces the number of invasive endomyocardial biopsies (EMBx) in the first year post-transplant
Adult (age ≥ 18 years) at the time of transplant
Recipient of a heart transplant at St. Paul's Hospital
Within 1 year of heart transplantation
Followed at the Post-Transplant Clinic in Vancouver, BC
Unable to provide informed consent
High immunological risk at transplant: positive flow crossmatch at time of transplant, or donor-specific antibodies (DSA) detected at time of transplant
Multi-organ transplant recipient (e.g., heart-kidney, heart-liver)
Clinical instability: hemodynamic instability, sepsis, or active severe wound infection at the time of a scheduled surveillance visit
Heart transplant recipients
Cohort
Prospective
Not listed
Number of avoided endomyocardial biopsies
Number of avoided endomyocardial biopsies because of HeartCare test integration
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
